Research programme: eye disorder therapies - Mimetogen Pharmaceuticals

Drug Profile

Research programme: eye disorder therapies - Mimetogen Pharmaceuticals

Latest Information Update: 24 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mimetogen Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Mucin stimulants; Nerve growth factor receptor modulators; Receptor protein tyrosine kinase agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Dry eyes; Glaucoma
  • Research Keratoconus; Retinitis pigmentosa

Most Recent Events

  • 21 Mar 2006 The programme is available for licensing worldwide (http://www.mimetogen.com)
  • 21 Mar 2006 Preclinical trials in Glaucoma in Canada (ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top